Description: JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is relmacabtagene autoleucel, an anti-CD19 CAR-T therapy for relapsed or refractory B-cell lymphoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.
Home Page: www.jwtherapeutics.com
Building B
Shanghai,
China
Phone:
86 21 5078 3699
Officers
| Name | Title |
|---|---|
| Dr. Yiping Li M.D. | Co-Founder & Interim Chairman |
| Mr. Min Liu | CEO & Executive Director |
| Cao Xiaoping Ph.D. | Senior Vice President of Tech Operations |
| Dr. Shaun Paul Cordoba Ph.D. | Senior VP & Chief Scientific Officer |
| Mr. Raymond J. Hage Jr. | Senior Vice President of Corporate Development |
| Mr. Mark J. Gilbert M.D. | Senior Advisor & Acting Chief Medical Officer |
| Mr. Qiang Ma | Senior VP & Chief Commercial Officer |
| Ms. Yun Qin | Senior Vice President of Clinical Sciences & Medical Services |
| Dr. Su Yang | Senior Vice President Of Clinical Research & PMO |
| Ms. Ka Man Ng A.C.I.S., A.C.S. | Company Secretary |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3454 |
| Price-to-Sales TTM: | 0.4538 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 323 |